

REMARKS


Claims 1-35 have been cancelled without prejudice or disclaimer. Claims 36-44 are currently pending based on their addition as new claims in this paper. The specification has been modified to address Examiner's objection requiring update of issued parent. New claims have replaced the issued claims to address Examiner's double patenting rejection. The new claims are supported by the specification, for example, at paragraphs [041] to [054] and Figures 2A-2C. Reconsideration of the pending claims is requested.

Fee Authorization

Should any extension of time and/or fee be necessary for timely submission of this paper, such extension of time is hereby requested, and the Commissioner is hereby authorized to charge **Deposit Account No. 01-2213 (order no. 4696C1)**. Any deficiency or overpayment should be charged or credited to this deposit account.

Date: August 17, 2004

Respectfully submitted,



Phil N. Makrogiannis
Reg. No. 47,766
Attorney for Applicants

CORRESPONDENCE ADDRESS

Customer Number: 22896
APPLERA CORPORATION
Applied Biosystems Group
Patent Department – M/S 432-2
850 Lincoln Centre Drive
Foster City, California 94404
TEL: 650-554-2164
FAX: 650-638-6677